. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Ophthalmology. 2014 Dec 24;122(4):662–668. doi: 10.1016/j.ophtha.2014.11.006

Table 3.

Changes in symptoms and signs in the subgroups with low or near-normal baseline subbasal nerve fiber length (SNFL) after 4 weeks of treatment with loteprednol etabonate.

	Low SNFL (<16.84 mm/mm²) n=8			Near-normal SNFL (=16.84 mm/mm²) n=9
	Baseline	4 Weeks	P value	Baseline	4 Weeks	P value
OSDI	50.6 ± 21.6	44.8 ± 24.9	0.27	53.3 ± 24.7	47.8 ± 26.2	0.15
SANDE Frequency	62.1 ± 22.5	56.4 ± 24.0	0.44	59.8 ± 17.6	47.4 ± 23.3	0.15
SANDE Severity	55.9 ± 22.8	59.4 ± 17.1	0.43	60.1 ± 17.4	50.0 ± 22.7	0.04
Corneal Fluorescein Staining (NEI scale)	6.5 ± 1.5	5.5 ± 3.9	0.46	6.7 ± 3.2	4.6 ± 2.9	0.01
Tear Break-up Time (seconds)	2.9 ± 1.0	2.4 ± 1.6	0.49	2.8 ± 2.0	2.5 ± 2.1	0.81
Conjunctival Lissamine Green Staining (NEI scale)	3.1 ± 3.7	2.8 ± 4.3	0.61	3.6 ± 3.9	1.4 ± 1.2	0.11
Schirmer’s Test (mm)	4.8 ± 3.5	2.7 ± 2.8	0.06	6.9 ± 8.0	1.8 ± 1.6	0.07